Aug 2026· Marine Drugs· Vol 24, pp. 284· 0 citations· 65 references
Medicine
TL;DR
Findings indicate how integrating genome mining, metabolomics, and molecular networking with targeted biosynthetic experiments can accelerate marine natural product discovery and unravel novel enzymatic functions and biosynthetic mechanisms in rare actinomycetes.
Abstract
Marine-derived rare actinomycetes are a chemically prolific yet underexploited source of structurally diverse secondary metabolites. In this review, rare actinomycetes are operationally defined as marine-derived non-Streptomyces actinomycetes that remain comparatively underexplored yet possess demonstrated or predicted capacity for specialized-metabolite biosynthesis. Genome sequencing has revealed that their biosynthetic potential greatly exceeds the range of metabolites recovered under standard cultivation conditions. However, many reported compounds remain only loosely associated with the gene clusters that encode them. This review provides a biosynthesis-centered perspective on marine-derived rare actinomycetes, focusing on secondary metabolites for which biosynthetic gene clusters (BGCs) or pathways have been proposed, experimentally assessed, or functionally validated. It focuses on compounds reported after 2017, along with earlier metabolites whose biosynthetic origins were resolved only later. Representative examples are organized by genus and structural class and weighed according to the level of evidence linking each metabolite to its BGC, ranging from bioinformatic prediction and metabolomic correlation to validation by gene inactivation, heterologous expression, and enzymatic characterization. The surveyed metabolites include polyketides, nonribosomal peptides, polyketide synthase-nonribosomal peptide synthetase (PKS-NRPS) hybrids, siderophores, angucyclines, anthracyclines, macrolides, diketopiperazine derivatives, and other unusual scaffolds. Collectively, these findings indicate how integrating genome mining, metabolomics, and molecular networking with targeted biosynthetic experiments can accelerate marine natural product discovery and unravel novel enzymatic functions and biosynthetic mechanisms in rare actinomycetes.
Current strategies for marine natural product discovery are summarized and emerging translational approaches integrating multi-omics technologies, pathway engineering, and AI-guided prioritization are highlighted, providing a roadmap for advancing marine Streptomyces research from descriptive omics-based exploration to...
M. Lertcanawanichakul, P. Bhoopong, Tuanhawanti Sahabuddeen et al.· Marine Drugs· 0 citations
Comparative genomic and biosynthetic analyses of 24 Talaromyces species reveal extensive diversification alongside selective conservation of secondary-metabolite pathways across Talaromyces and provide a genomic framework for prioritizing species and BGCs for antifungal natural-product discovery and biocontrol-oriented...
B. Chellappan, Hashem Al-Sheikh· Journal of Fungi· 0 citations
This work analysed 939 cyanobacterial genomes spanning 11 orders and five habitat types to identify taxonomic and ecological hotspots of biosynthetic potential and link phylogeny, ecology and genomic features to prioritise taxa, habitats and biosynthesis pathways for future natural product discovery.
Rachel Mizzi, B. A. Neilan, L. Pearson et al.· bioRxiv· 0 citations
The effectiveness of integrated genome-mining strategies for prioritizing cryptic biosynthetic gene clusters is demonstrated and the remarkable biosynthetic potential of newly identified Streptomyces isolates as a source of novel natural products is highlighted.
Nada S. Al-Theyab, Haila M. Alnassar, Mohanad A. Ibrahim et al.· Frontiers in Microbiology· 0 citations
Rare actinobacteria are promising sources of specialized metabolites, yet genome mining still prioritizes genomes encoding many biosynthetic gene clusters (BGCs) rather than clusters that are distant from characterized chemistry. Here, we describe the isolation of a novel Jiangella strain reported from a marine, animal...
Ruggero Baviera, F. Capri, Paola Galluzzo et al.· Marine Drugs· 0 citations